NYTIMES Just for the record, here's what I wrote in the summer and the reply
Kathleen
Re: Lyme disease
Date:
Tue, 24 Aug 1999 14:54:28 -0400
From:
"Kathleen M. Dickson" <kathleen...@snet.net>
Organization:
SeCT Chronic Lyme Group
To:
Nicholas Wade <niw...@nytimes.com>
References:
1
Nicholas Wade wrote:
>
> Dear Kathleen
> Thanks for your email. I'm sorry to hear you've been disabled with Lyme
> disease.
> We might well be interested in doing a story - it depends on what you
> have. Could you tell me the gist of it? Email is fine or if you prefer to
> call, my number is 212 556 4302.
>
> - Nicholas Wade
>
Lyme disease is a most dreadful disease and
the majority of docs minimize it because Allen Steere and
the guys at Stony Brook want all the NIH research money available
to go into researching vaccine candidates and developing diagnostic
test kits. Nobody wants to help patients and those
that do are being persecuted.
This is a sort of proclamation or epetition and it is still in
the works. I am trying to put together an email list of legislators to
have my fellow-sufferers help with an email campaign.
Meantime, here is what's going on with Lyme disease. At least a
partial picture: This is a letter sent to me from
a joker in the LD newsgroup (sci.med.diseases.lyme)
who could be anybody, really, but acts like he's a plant
by the Steere Camp and my response.
From Frank:
Jopn has a right to speak his views on this subject since there is many
LLMD's
out there that are getting rich off this disease. These LLMD's are
hurting the
true doc's who want to find out whats wrong with a person and treat
them
without being called a "moron" and a non-LLMD because you can't get him
to say
you have chronic Lyme.
-Frank
Dear Frank,
Of course that's true Frank.
But at some point in his life and yours,
you will grow up and understand that there is a need
to support what you are saying with evidence and just
plain stop whining. When you both progress emotionally
to the point of self-awareness you will not want to look back
on this time in your life.
You obvously have not read my posts about who is
getting rich off of this disease.
A lot of docs I know are Morons. Some are even worse:
Jan Evans at Yale does Independent Medical Evals for
insurance companies and asks that just the patient records be sent.
Not the patient.
Lyme disease is supposed to be a clinial diagnosis.
The Ins Co and the Yale doc know exactly what they
are doing.
What's her fee for 10 minutes worth of work?
We know she is going to say No Lyme, because that way
she'll continue to get more referrals.
The last I heard was $350 and hour and they charge a
standard two hours.
No follow up visits at the usual $100 per 1/2 hour that most
LLMDs have to charge. Who is making more money per patient hour?
$$$$$ Here's the Evidence $$$$$$.
Recently some scientists in New York have initiated an attempt to have
licenses revoked of some Lyme-Literate Physicians in New York. This
presents a problem because there are few in the northeast, as
elsewehere, who have the courage to face the harrassment of these SUNY
based and other university-based researchers as well as insurance
companies in order to treat Lyme disease patients. These
Lyme-Literate Physicians, the ones criticized by these highly funded
researchers are the ones who have the experience and expertise that
reflects the state of current knowledge of treatment.
We herein point out that some of these highly funded researcher’s
efforts and focus is in discovering molecules of interest to vaccine
manufacturers and for sale in diagnostic test kits. The evidence
follows.
We contend that Alan Barbour, Ray Dattwyler, Ben Luft, Leonard Sigal,
Erol Fikrig and Allen Steere, Robert Schoen,and others in the
Overdiagnosed/Overtreated Camp; the self-proclaimed experts who are
getting most of the funding regarding Lyme disease, are interested in
the commercial value of this disease and not in curing patients.
We seek a review of the results of government (NIH) funding to these
self-proclaimed Lyme Disease experts who seek molecules and diagnostic
methods to patent for profit.
We herein present a protocol for deliverance of patients from people who
claim Lyme disease becomes an autoimmune disease for which antibiotics
do not cure, or from whom a diagnosis of NOT LYME benefits insurance
companies and is more profitable per patient minute than treating Lyme
disease patients.
$$$$$ Patents and Grants $$$$$$$$
Patents of Alan Barbour (of the ALDF).
Barbour owns a patent for a rOSP A and then some. Alan Barbour had this
to say about Claire Fraser's publication of a Borrelia burgdorferi
genome in Nature Dec 1997:
"...But those who expecting to find in B.b. a rich vein of gold in which
to mine virulence determinants have to be disappointed [OSP A is an
immune irritant- my parens-KMD].....The results encourage study of a
more metabolically competent spirochete, such as the Spirocheta
aurentia, for a better understanding of how this ancient group of
bacteria evolved, and to identify catalytic molecule of industrial
importance."...
[What he is suggesting is that we don't study at a spirochete that
causes a disease and why, but rather one that does not cause disease
because it may have commercial value. That's because he has a patent for
recombinant OSP-A.]
PAT. NO. Title
1- 5,846,946 Compositions and methods for administering Borrelia DNA
2- 5,777,095 Osp A and B Sequence of Borrelia burgdonferi strains ACA1
and IP90
3- 5,688,512 Borrelia antigen
4- 5,585,102 Flagella-less borrelia
5- 5,582,990 DNA encoding borrelia burgdorferi OspA and a method for
diagnosing borrelia burgdorferi infection
6- 5,571,718 Cloning and expression of soluble truncated variants of
Borrelia OspA, OspB and Vmp7
7- 5,523,089 Borrelia antigen
8- 5,436,000 Flagella-less borrelia
9- 5,246,844 Virulence associated proteins in Borrelia burgdorferi (BB)
The Patents of Erol Fikrig - Yale
PAT. NO. Title
1- 5,807,685 OspE, OspF, and S1 polypeptides in Borrelia burgdorferi
2- 5,747,294 Compositions and methods for the prevention and diagnosis
of Lyme disease
3- 5,656,451 OspE, OspF, and S1 polypeptides in borrelia burgdorferi
4- 5,618,533 Flagellin-based polypeptides for the diagnosis of lyme
disease
The Endeavors of Ray Dattwyler and Ben Luft, SUNY Stony Brook
researchers who own Brook Biotechnologies.
Patent Applications of Ben Luft, SUNY, Stony Brook.
LUFT,DR. BENJAMIN J.
Spon: NI Allergy + Infectious Diseases
From: 19980901 To: 19990831 Direct: 311446
Indirect: 88834
VACCINE INTERVENTION FOR LYME
BORRELIOSIS
LUFT,DR. BENJAMIN
Spon: National Institutes of Health
From: 19990701 To: 20000630 Direct: 111148
Indirect: 40902
VACCINE INTERVENTION FOR LYME BORRELIOSIS
NIH Grants Fiscal Year 1997 for Dattwyler and Luft's Company Brook
Biotechnologies
http://silk.nih.gov/silk/brownbooks/sbir/org/fy97
NEW YORK BROOK BIOTECHNOLOGIES, INC. # 1 $324,790
Fiscal year 1995 http://silk.nih.gov/silk/brownbooks/sbir/org/fy95
NEW YORK BROOK BIOTECHNOLOGIES, INC. # 1
$99,840
More funding for Raymond Dattwyler:
http://fundedresearch.cos.com/cgi-bin/NIH/getRec?P01NS340929002
Principal Investigator and Address: DATTWYLER, RAYMOND J
SUNY @ STONY BROOK HEALTH SCIENCES CENTER, T12-02
STONY BROOK, NY 11794-8121
Initial Review Group: ZNS
Performing Organization:
STATE UNIVERSITY NEW YORK STONY BROOK
Grant Title: NEUROLOGIC ASPECTS OF LYME DISEASE IN NORTH AMERICA
Grant Expires in: 2 Year(s)
These two links show you the two grants that went to Luft:
http://fundedresearch.cos.com/cgi-bin/NIH/getRec?M01RR107100015
http://fundedresearch.cos.com/cgi-bin/NIH/getRec?R01AI37256
Where to get the info on the some of the grant money Brook
Biotechnologies received in 1997
http://www.sba.gov/gopher/Innovation-And-Research/Awd97/awdny.txt
29146 HHS Brook Biotechnologies, Inc. *** $633,237 ***
Long Island High Tech Incubato 25 East Loo Phase: 2
Stony Brook NY 11790-335 Minority: Woman:
Topic: Recombinant Based Elisa--Diagnosis of Lyme Borreliosis
Patents Pending for Ben Luft, Partner in Brook Biotechnologies:
http://www.research.sunysb.edu/research/data/pendaps.txt
LUFT,DR. BENJAMIN J. *
Spon: National Institutes of Health
From: 19981201 To: 19991130 Direct: 229409
Indirect: 90724
GENETIC IDENTIFICATION AND DELINEATION OF HUMAN
PATHOGENIC CLONES OF BORELIA BURGDORFERI
[Where are the results? There are none. Molecular mimicry in LD is not
proven. These are recent articles which demonstrate that molecular
mimicry in Lyme has the scientific value equivalent to male bovine
dung.]
"Cell Immunol 1999 May 25;194(1):118-23
Cross-reactivity of Borrelia burgdorferi and myelin basic
protein-specific T cells is not observed in borrelial encephalomyelitis.
Pohl-Koppe A, Logigian EL, Steere AC, Hafler DA
Center for Neurologic Diseases, Brigham and Women's Hospital, Boston,
Massachusetts, 02115,
USA. Annette.P...@kk-i.med.uni-muenchen.de
Borrelial encephalomyelitis, a rare manifestation of Lyme borreliosis,
may present as a multiple sclerosis (MS)-like disease. It is postulated
that in MS, inflammation of the white matter is
caused by a T-cell response directed to myelin antigens. Here, we
examined whether a T-cell autoimmune response may play a pathogenetic
role in Borrelia-associated white matter disease mediated by
cross-reactivity between myelin basic protein (MBP) and B. burgdorferi.
We
generated a total of 1760 short-term T-cell lines against B. burgdorferi
or MBP from two patients with Borrelial encephalomyelitis and
compared these with three patients with late Lyme disease,
one patient with transverse myelitis, eight patients with MS, and four
healthy controls. While a few T-cell lines recognized both B.
burgdorferi and MBP, T-cell clones from these lines
responded only to the antigen of the original stimulation. Thus, our
data do not provide evidence for cross-reactivity between MBP
and B. burgdorferi. Copyright 1999 Academic Press."
Molecular Mimicry Bytes the Weenie
___________________________________________________-
"Science 1998 Jul 31;281(5377):703-6
Identification of LFA-1 as a candidate autoantigen in
treatment-resistant Lyme arthritis.
Gross DM, Forsthuber T, Tary-Lehmann M, Etling C, Ito K, Nagy ZA, Field
JA, Steere AC, Huber BT
Department of Pathology, Tufts University, Boston, MA 02111 USA.
Treatment-resistant Lyme arthritis is associated with immune reactivity
to outer surface protein A (OspA) of Borrelia burgdorferi, the agent
of Lyme disease, and the major histocompatibility complex class II
allele DRB1*0401. The immunodominant epitope of OspA for T helper cells
was identified. A homology search revealed a peptide from human
leukocyte function-associated antigen-1 (hLFA-1) as a candidate
autoantigen. Individuals with treatment-resistant Lyme arthritis,
but not other forms of arthritis, generated responses to OspA,
hLFA-1, and their highly related peptide epitopes. Identification of the
initiating bacterial antigen and a cross-reactive autoantigen may
provide a model for development of autoimmune disease."
____________________________________
Nothing yet, eh, Allen?
Keep plugging for the funds, though.
_____________________________________
More About Where Steere’s endeavor lead him:
https://www-commons.cit.nih.gov/crisp/
Grant Number: 5R03TW00514-03PI
Name: STEERE, ALLEN C.PI Title: Project
Title: LYME BORRELIOSIS IN RUSSIA
Abstract: DESCRIPTION (adapted from investigator's abstract): The
specific aims of the parent grant are to describe the clinical
manifestations of Lyme Disease in patients in New England, to
develop specific diagnostic tests, and to determine appropriate
treatment regimens for the illness. Since 1986, Dr. Steere, the
Principal Investigator of the parent grant, has participated in a
cooperative exchange with physicians at the Rheumatology Institute
in Moscow under the auspices of the U.S.-U.S.S.R.
Biological Health Agreement. It is now known that a considerable portion
of the worldwide nosoarea of Lyme borreliosis is situated within
the former Soviet Union. The infection there may be caused by any of the
three currently identified groups of the B. burgdorferi sensu latu
complex, including B. burgdorferi sensu stricto, B. garinii, and B.
afzelii.
However, the characteristics of the disease, particularly the late
manifestations of the illness, are incompletely described in Russia,
and for the most part, accurate diagnostic testing is not yet available
there. In the proposed study, the clinical manifestations of Lyme
borreliosis in Russian patients will be described based on a referral
network of patients seen at the Rheumatology and Neurology Institutes in
Moscow, and patients seen at the Lyme Disease Center at Ekaterinburg, a
highly endemic area in the Ural Mountains, about 1,000 miles east of
Moscow. A Lyme disease diagnostic laboratory will be developed in
Moscow, and sensitive and specific diagnostic criteria for ELISA
and Western blotting tests will be developed, based on Russian case and
control subjects. Skin biopsy samples of erythema migrans skin lesions
will be cultured, and joint fluid and cerebrospinal fluid samples will
be tested by PCR in an effort to identify the groups of the B.
borrelia burgdorferi sensu latu complex which cause this infection in
Russia. Finally, the clinical data will be correlated with the
laboratory information in an attempt to determine whether particular
spirochetal groups cause different clinical pictures with different
serologic responses in Russia. These studies are important both to
understand
variations of this infection in different parts of the world and to
aid in the diagnosis and treatment of Russian patients with this curable
infection.
Institution: NEW ENGLAND MEDICAL CENTER
750 WASHINGTON ST
BOSTON, MA 02111
Fiscal Year: 1997
Department: Project Start: 30-SEP-95
Project End:
29-SEP-99
ICD: FOGARTY INTERNATIONAL CENTER
IRG: ICP
______________________________________________
You know what Frank? I don't know for sure, but I bet
Allen is not doing this as a philanthropic endeavor. Are their any labs
in Russia which he has ownership? Did the Russians have to purchase
an agreement to license Steere’s methods?
We think this is a cute sell: “this cureable infection”. Lyme disease
is not always a cureable infection or he and others like him would not
be getting millions of dollars in grant money to study it. Some
infectious
diseases docs contend that you never get rid of Lyme.
_________________________________________________
The Good Old Days, Before Lyme disease was a Rich Vein of Gold from
which to
mine diagnostic and vaccine biomolecules of commercial/industrial value:
Seronegative Lyme disease. Dissociation of specific T- and B-lymphocyte
responses to Borrelia burgdorferi [see comments]
***Dattwyler RJ***, Volkman DJ, Luft BJ, Halperin JJ, Thomas J,
Golightly MG
N Engl J Med 1988 Dec 1 319:22 1441-6
Abstract
The diagnosis of Lyme disease often depends on the measurement of
serum antibodies to Borrelia burgdorferi, the spirochete that causes
this disorder. Although prompt treatment with antibiotics may
abrogate the antibody response to the infection, symptoms persist in
some patients. We studied 17 patientsvwho had presented with acute
Lyme disease and received prompt treatment with oral antibiotics, but in
whom chronic Lyme disease subsequently developed. Although these
patients had clinically active disease, none had diagnostic levels
of antibodies to B. burgdorferi on either a standard enzyme-linked
immunosorbent assay or immunofluorescence assay. On Western blot
analysis, the level of immunoglobulin reactivity against B. burgdorferi
in serum from these patients was no greater than that in serum from
normal controls. The patients had a vigorous T-cell proliferative
response to whole B. burgdorferi, with a mean ( +/- SEM) stimulation
index of 17.8 +/- 3.3, similar to that (15.8 +/- 3.2) in 18 patients
with chronic Lyme disease who had detectable antibodies. The T-cell
response of both groups was greater than that of a control group of
healthy subjects (3.1 +/- 0.5; P less than 0.001).
We conclude that the presence of chronic Lyme disease cannot be
excluded by the absence of antibodies against B. burgdorferi and
that a specific T-cell blastogenic response to B. burgdorferi is
evidence of infection in seronegative patients with clinical
indications of chronic Lyme disease."
NOW Dattwyler has this to say:
Chembio Takes Lead In Rapid-Test Race / First to get FDA OK online
disease kit
By Michael Unger. STAFF WRITER
Biotechnology executive Tom Haendler says he knew he was in the right
business when even the monster movie he watched on a TransAtlantic jet
portrayed home pregnancy tests like the one his Long Island company
manufactures. While watching "Godzilla" as he returned from a
medical
technology show in Europe last year, the picture's hero goes into a
drugstore
and buys over-the-counter home pregnancy tests to determine whether the
monster terrorizing New York City is pregnant. Said Haendler, president
of Chembio
Diagnostics Systems, "If this [pregnancy test] made the movie, then I'm
sure we're on the right track."
Now, privately held Chembio of Medford, in its latest venture into
the
rapidly growing diagnostic-test industry, has a deal with a large
pharmaceutical company in New Jersey, Carter Wallace, to market the
first
rapid Lyme disease test.
The worldwide market for rapid diagnostic tests for both home and
professional use is far more than $2 billion, analysts say. And while
it is far from being alone in the market of fast tests,Chembio has made
rapid biotech pregnancy test kits for both the home market and doctors'
offices, hospitals and clinics for several years. Now it has taken the
lead in quick tests for Lyme disease.
The company, formed with venture capital investors headed by
company chairman Lawrence Siebert, has developed numerous other rapid
tests for tuberculosis, ulcers and newly emerging diseases and parasites
now sometimes found in the United States, such as malaria, Chaga's
disease
and Dengue Fever.
Just last week, Chembio became the first company to win the U.S.
Food
and Drug Administration's approval to market a simple test to show
whether
someone has been bitten by a tick infected with Lyme disease. The test
shows positive or negative for the presence of antibody markers for the
Lyme organism within 20 minutes. It also gives doctors a signal whether
to start crucial antibiotic treatment immediately instead of potential
delays at an outside laboratory. Even so, the FDA recommends that
positive
Lyme results on the Chembio rapid blood test be confirmed with a second
test
at a clinical laboratory.
For the moment, Chembio is alone in the field with its Lyme test;
but other companies are hot on the trail. Chembio's Lyme test is better
than 95 percent accurate, according to clinical tests, and is the first
rapid Lyme test to pass FDA muster. It will be marketed starting in
April,
Chembio says, for doctors' offices, hospitals, clinics and reference
laboratories. An over-the-counter version for consumers' home use is
in the works. The price has not been determined.
The test uses technology developed by Lyme disease experts at the
State University at Stony Brook medical school and Brookhaven National
Laboratory. It was developed jointly by Chembio and by Brook
Biotechnologies Inc. in the Long Island High Technology Incubator in
Stony Brook.
"That's our test," said Dr. Raymond J. Dattwyler, president of
Brook Biotechnologies who also heads the Lyme Disease Center at the
State
University at Stony Brook's Health Sciences Center. Dattwyler and Dr.
Benjamin J. Luft, chairman of medicine at Stony Brook, are the
inventors,
along with Dr. John Dunn of the Brookhaven National Laboratory Biology
Department. The patents are owned by the State University and Brookhaven
National Laboratory.
At the Chembio plant on Horseblock Road, several dozen women in
blue
pharmaceutical garb assemble the various kinds of test kits by hand.
The
company's platform technology requires only a drop of blood, urine or
mucous on a treated membrane strip to show negative or positive
results.
Chembio scientists Sat Nam S. Hanjan, Mewa Singh and Hema Mana explain
that the biochemical reactions begin to appear on the small plastic
indicators within
a minute or two and usually take no more than 15 or 20 minutes to fully
develop and complete. The kits are manufactured in the Medford plant in
batches of 10,000 to 100,000.
"We're hoping that many of these tests eventually will be available
for consumer purchase for use at home," Hanjan said. Chembio recently
won a $100,000 research grant from the federal government to develop a
rapid biotech test for new strains of drug-resistant tuberculosis. A
rapid AIDS test also is in the works.
The company believes it is on the leading edge of the trend toward
ultra-fast testing. "It's the way everything is going to go," says Avi
Pelossof, Chembio's marketing director. "It's a great industry to
be in," said Haendler. "And we're in it at the right time." "
Frank, The man is not spending his time trying
to discover what works in terms of treatment for Lyme disease.
I mean, just by virtue of the time he must
be spending at SUNY and at Brook Biotechnologies doing
this test kit stuff.
This letter was sent soon after a conversation I had with a Victor
Berardi at Imugen, as I was complaining that we patients get
always negative results for Lyme from his lab.
Imugen uses a German strain and a strain from Guilford CT
instead of the three CDC- recommended strains for antigen source for
Western Blotting.
This email was sent within a company in CT.
"Sent: Friday, July 02, 1999 2:59 PM
Subject: CDC Lyme Disease Study
"This summer, Dr. Vijay Sikand and Dr. Allen Steere will be
working on a CDC and NIH supported Lyme Disease study for which
they are seeking patient volunteers. This study has been approved by
Tufts/New England Medical Center's Institutional Review Board.
They are primarily interested in patients with physician diagnosed
erythema migrans, in whom they will be studying pathogenesis of
disease, histopathology, molecular and genetic diversity of Borrelia
burgdorferi isolates, cell-mediated immune factors, and serology, in the
setting of clinical presentation. These patients will have skin
biopsy of the lesion (small enough to be dressed with a
bandaid, no sutures) as well as bloodwork on the day of presentation.
Lyme disease treatment will be initiated at that time. Only one
follow-up visit is required for convalescent bloodwork, 2 to 4 weeks
later. The grant provides for a $100 payment to these volunteers.
Since specimens must be sent by overnight courier to Boston, patients
must be seen no later than about 3:00 p.m. Monday-Friday. Dr. Sikand's
office is located next door to Brooks Pharmacy at
Flanders Four Corners in East Lyme."
Patients with Chronic Lyme disease contend that if Dr. Steere was truly
interested in the relative virulence, he would ask the patients to come
back at 6 months, 1 year, 2 years, etc., to see which strains have
the worst remaining effect on the patient. If he was looking for a
better vaccine candidate based on virulence, he would have them come
back at later points in time.
Dr. Steere has been known to laud the qualities of Imugen at
conferences in Long Island. Imugen uses FR/1, a strain from Germany
and a strain from Guilford, CT. We contend that these strains will
not produce the same antibody profile in patients in southeastern CT.
Our patients will not have been exposed to surface antigens
characteristic of European strains of B.b.
We later found out that Imugen is in a partnership with CORIXA why
http://www.corixa.com/parpro/partnered.asp
Target Product: Reference diagnostic for detection of certain
tick-borne diseases Status: Development
Partner: IMUGEN, Inc.
That explains why Steere was down here looking for new strains.
Corixa and others are looking for markers of infection; to patent
other commercially viable diagnostic test kit antibodies/ biomolecules.
Check out Corixa on Schwab.com. You can get a free 7 day trial. They
are CRXA on the NYSE.
from a April 7, 1998 Press release:
"Corixa Corporation Establishes Diagnostics Collaboration with Imugen
"...The agreement provides Imugen with an exclusive license,
including the right to sub-license these recombinant antigens
for reference laboratory testing in the US and Canada
in exchange for a share of revenues from any diagnostics
kits or blood screening tests that are developed as a
result of this collaboration..."
So, Who's making money off of Lyme disease, Frank?
Do you think you have the self respect to at least
read this info and consider what it all means?
Kathleen
Dear Mr. Wade,
These guys, Steere, Dattwyler, Schoen, all want to say
people who "had" Lyme disease, now have something else if
they still have symptoms.
That's why Atty Gen Blumenthal held a public hearing. He
knows from talking to patients that these guys are
trying to say that Lyme patients are just depressed or something.
Or, have Chronic Fatigue Syndrome (an autoimmune disease)
or Fibromyalgia (an autoimmune disease), because if these
cases spontaneously mutate into an autoimmune disease from
an infectious disease, they increase the surveillance numbers
and therefore the funding for their specialties: Rheumatology
and Immunology.
They are also trying to take down our LLMDs (Lyme Literate doctors)
because they would interfere with their activities.
Notice how Ray Dattwyler first publishes about how Lyme
can be present in the absense of positive Western Blot,
but when he creates a diagnostic test kit, he is 95% accurate.
How convenient.
You can't even get a diagnosis of Lyme diseaes in Southeastern CT.
The docs are too scared of insourance companies hassling them
and in going against the "Standard of Care"
dictated by Steere. They write "localized dermatitis" in their charts
and give the patient 21 to 30 days of doxy and send them on their way.
When they come back not better, they say, "I'm glad you're better.
Have a nice life."
These same guys, Steere, Dattwyler, etc, who decl;are themselves to be
experts in the Standard if Care, when in fact, in the past two
International
conferences on Borreliosis, there was no consensus on what works
for Lyme disease. One was in Munich and one was in NYC, held by
the Lyme Disease Foundation, Hartford. In the latter one, several docs
took
turns statiung what their treatment modalities were. This is
becasue other docs in attendence want to know what's working for
other people. Nobody knows what will work. At the conclusion of
the Chronic Neuroborreliosis section in Munish, the consensus
was "No Consensus". However Ray Dattwyler was there and I heard that
he walked up to a bunch of people and started talking about how
important he was to the point where everyone else just stood there
with their mouths open... Bowled over by his arrogance...
How can these Rheumatologists proclaim to know, especially when they
are concentrating on diagnosis and not treatment?
It's more profitable NOT to treat.
Ask Jan Evans at Yale. Ask her how much she makes
doing an independent eval for an Ins Co in a Lyme case?
I have more information.
Intersted?
Many Thanks,
Kathleen
HIS REPLY:
Subject:
Lyme disease story
Date:
Tue, 24 Aug 1999 15:25:26 -0400
From:
Nicholas Wade <niw...@nytimes.com>
To:
kathleen...@snet.net
References:
1
Dear Kathleen
Thanks for your email. You raise some interesting points. In my
view
there is not yet a story here for us (a judgment which in no way
reflects
on the validity of your complaints).
Thank you for letting us know about the issue, and I will now
keep an eye
on it.
- Nicholas Wade
User763213
first the lyme community and all doctors have to stop beating each other up. A
cure is out there and it should have been found long ago . bacterial
infections are not cancerous they are parasites that can be eradicated with
systenatic anti-microbial therapy. its that simple